Stock Market Reviews

CNTA (Centessa Pharmaceuticals plc) News

Get the latest news, insights, and market updates on CNTA (Centessa Pharmaceuticals plc). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
  ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advanci
  Nov 5, 2025 - $CNTA
• Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls
  Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls
  Oct 28, 2025 - $CNTA
• Centessa Pharmaceuticals (CNTA): Reviewing Valuation After 46% Three-Month Share Price Surge
  Centessa Pharmaceuticals (CNTA) stock has quietly gained steam over the past quarter, delivering a 46% climb in that time. Investors may be looking beyond short-term volatility and focusing on the company’s long-term pipeline prospects and recent momentum. See our latest analysis for Centessa Pharmaceuticals. Centessa’s latest share price of $22.86 reflects a remarkable run, with a 45.7% share price return over the past quarter in addition to a 44.6% total shareholder return in the last year...
  Oct 17, 2025 - $CNTA
• LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data
  Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price target of $39.00. In Q2 2025, Centessa Pharmaceuticals reported that the company had $404.1 million in cash and investments, which […]
  Sep 15, 2025 - $CNTA
• Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
  BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET. The live audio webcast of this event, as well as an archived recor
  Sep 3, 2025 - $CNTA
• Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
  Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
  Aug 29, 2025 - $CNTA
• Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
  Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acute
  Aug 12, 2025 - $CNTA
• Why Alkermes Tumbled On Its Positive Narcolepsy Study
  Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.
  Jul 21, 2025 - $CNTA
• Centessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical Trials
  Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best low priced pharma stocks to buy now. On July 4, Nxera Pharma Co. Ltd., which develops and sells pharmaceutical products, announced that it is set to receive $4.8 million in milestone payments from Centessa Pharmaceuticals. These payments stem from their existing research collaboration and followed Centessa’s initiation […]
  Jul 15, 2025 - $CNTA
• Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
  Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Dru
  Jul 4, 2025 - $CNTA